Trends of Mortality in End-Stage Liver Disease - China, 2008-2020.
China
cirrhosis
end-stage liver disease
liver cancer
mortality
Journal
China CDC weekly
ISSN: 2096-7071
Titre abrégé: China CDC Wkly
Pays: China
ID NLM: 101767554
Informations de publication
Date de publication:
28 Jul 2023
28 Jul 2023
Historique:
received:
16
05
2023
accepted:
15
06
2023
medline:
18
8
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
Liver cancer and cirrhosis represent the most prevalent forms of end-stage liver diseases (ESLDs). Notably, in China, deaths attributed to ESLDs contribute significantly to the global mortality rate of these disorders. Enhanced comprehension of the mortality profile associated with ESLDs in China could provide crucial insights into intervention prioritization, which could in turn help reduce the overall global burden of these diseases. Data were obtained from China's Disease Surveillance Points system. The presentation includes both crude and age-standardized mortality rates, stratified by sex, residential location, and region. Using Joinpoint Regression, trends in annual mortality rates were estimated from the period of 2008 to 2020 and expressed as the average annual percentage change (AAPC). In 2020, the gross mortality rate of ESLD stood at 30.08 cases per 100,000 individuals. A higher age-standardized ESLD mortality rate was observed in males and rural populations in comparison to their female and urban counterparts, respectively. Noticeably, the highest mortality rates associated with liver cancer and cirrhosis were reported in South and Southwest China, respectively. A positive correlation was noticed between age-specific ESLD mortality rates and advancing age. Interestingly, an annual decrease in the ESLD mortality rate was observed from 2008 to 2020. In urban contexts, the AAPC of cirrhosis was noted to be higher than that of liver cancer. The mortality rate associated with ESLDs in China decreased between 2008 and 2020. Nevertheless, the death burden attributable to ESLD continues to be alarmingly high. Future initiatives should prioritize the reduction of ESLD mortality in particular populations: males, elderly individuals, and those residing in rural regions of South and Southwest China. The emphasis of future interventions should be placed on antiviral therapy for adults diagnosed with viral hepatitis, and on the prevention of hepatitis B virus (HBV) infection across all demographics.
Identifiants
pubmed: 37593126
doi: 10.46234/ccdcw2023.128
pii: ccdcw-5-30-657
pmc: PMC10427498
doi:
Types de publication
Journal Article
Langues
eng
Pagination
657-663Informations de copyright
Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023.
Déclaration de conflit d'intérêts
Prof. Rao HY has received speaking fees from Bristol-Myers Squibb, Gilead, and AbbVie. The other authors declared no conflicts of interest.
Références
Biomed Environ Sci. 2020 Jan 20;33(1):1-10
pubmed: 32029053
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
BMJ Open. 2018 Feb 8;8(2):e020490
pubmed: 29439081
J Clin Transl Hepatol. 2019 Dec 28;7(4):322-328
pubmed: 31915601
Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):938-961
pubmed: 31941257
J Viral Hepat. 2018 Sep;25(9):1008-1016
pubmed: 29624818
Ann Transl Med. 2020 Apr;8(8):564
pubmed: 32775365
JAMA Netw Open. 2019 Jun 5;2(6):e195718
pubmed: 31199446
Chin Med J (Engl). 2021 Mar 17;134(7):783-791
pubmed: 33734139
Liver Int. 2017 Feb;37(2):159-172
pubmed: 27748564
Hepatology. 2020 Nov;72(5):1605-1616
pubmed: 32043613
Int J Infect Dis. 2017 Dec;65:15-21
pubmed: 28935244
Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415
pubmed: 35180382
Glob Health Med. 2021 Oct 31;3(5):270-275
pubmed: 34782868
Cancer Med. 2019 Sep;8(12):5787-5799
pubmed: 31385465
China CDC Wkly. 2022 Apr 15;4(15):306-311
pubmed: 35548455
Eur J Gastroenterol Hepatol. 2021 Aug 1;33(8):1117-1123
pubmed: 33905216